Welcome to our dedicated page for My Size SEC filings (Ticker: MYSZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
My Size, Inc. filings document the public-company reporting record for a Nasdaq-listed fashion technology and commerce issuer. The company’s Form 8-K filings report operating results, preliminary financial information, Regulation FD communications, shareholder letters and Nasdaq listing-compliance notices related to its common stock.
Proxy and annual-meeting filings cover board elections, equity incentive plan amendments, share-reserve provisions, auditor ratification and stockholder voting results. The filing record also includes late-filing notices for periodic reports, together with exhibits and Inline XBRL cover-page data that support the company’s formal disclosure of results, governance matters, capital structure and reporting status.
My Size, Inc. is soliciting proxies for its Annual Meeting of Stockholders to be held on July 21, 2026 in Tel Aviv. The board asks shareholders to vote FOR election of two Class II directors, advisory approval of executive compensation, authorization for a 1-for-2 to 1-for-30 reverse stock split, authorization to issue blank check preferred stock, and ratification of Somekh Chaikin as auditors.
The proxy statement sets the record date as May 27, 2026, states 4,818,164 shares outstanding as of that date, and discloses ownership and compensation tables, committee compositions, and equity awards. The board recommends approval of all listed proposals.
MySize, Inc. reported strong top-line growth for the first quarter of 2026 while remaining unprofitable. Revenue rose 62% year-over-year to about $2.39 million, driven mainly by fashion e-commerce operations and the consolidation of Percentil.
Gross profit more than doubled to roughly $940 thousand, with gross margin improving to 39.3% from 28.4%, reflecting better profitability on each sale. Operating expenses also increased across research and development, sales and marketing, and general and administrative functions, supporting technology investments and integration activities.
Net loss widened to approximately $1.48 million from about $1.06 million a year earlier, and cash, cash equivalents and restricted cash totaled roughly $910 thousand as of March 31, 2026. Management highlighted continued integration of Percentil and ShoeSize.Me and growth at Orgad and Naiz Fit as MySize builds an AI-driven, multi-channel fashion technology platform.
My Size, Inc. reported sharply higher revenue but deeper losses and mounting liquidity pressure for the three months ended March 31, 2026. Revenue rose to $2.4 million from $1.5 million, mainly from its fashion e-commerce platform and the addition of Percentil’s resale activity.
Gross profit more than doubled to $0.9 million, yet operating expenses increased faster, pushing operating loss to $1.4 million and net loss to $1.5 million, both wider than a year earlier. Cash, cash equivalents and restricted cash fell to $0.9 million from $2.6 million at year-end.
Management states there is substantial doubt about the company’s ability to continue as a going concern, expecting continued losses and negative cash flows. The company is relying on cost controls, product commercialization and additional financing, including its At The Market equity program, to fund operations.
MySize, Inc. files its annual report describing a fashion technology platform built around four units: Naiz Fit size-and-fit SaaS, Orgad Amazon overstock commerce, Percentil second-hand recommerce, and Ten Peacks apparel distribution in Israel. The company highlights acquisitions of Percentil’s production unit, ShoeSize.Me, and the formation of Ten Peacks to deepen its integrated data-driven fashion platform.
MySize reports heavy losses and an accumulated deficit, and its auditor raises substantial doubt about its ability to continue as a going concern. Management discloses it must raise additional capital to fund operations, while continuing to invest in AI sizing, recommerce infrastructure, and marketplace pricing technologies.
SIZE, INC. filed a Form 12b-25 notifying the SEC that its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 could not be timely filed due to delays in collecting and compiling certain required information. The company states it intends to file within the 15-day extension period provided by Rule 12b-25.
My Size, Inc. reported that Nasdaq notified the company its common stock closed below $1.00 for 30 consecutive trading days, triggering a minimum bid price deficiency. The company has 180 days, until August 31, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for 10 consecutive business days.
The company said the notice does not affect its current operations, customers, financial position, or the continued trading of its shares on Nasdaq under the symbol MYSZ. Management reiterated a focus on execution, revenue quality, and higher-margin activities. My Size generated approximately $10 million of revenue in 2025, with its Orgad business operating at about 40% gross margin, and its 10peaks subsidiary generating roughly $150,000 of revenue at about 65% gross margin before operating expenses. Management currently estimates 10peaks could reach around $3 million in annual revenue based on current commercial assumptions.
My Size, Inc. received a notice from Nasdaq that its stock no longer meets the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market. This follows 30 consecutive business days with a closing bid price below that level.
The company has 180 calendar days, until August 31, 2026, to regain compliance by achieving a closing bid of at least $1.00 for 10 consecutive business days. If it still does not comply, it may qualify for an additional 180-day period if it meets other Nasdaq listing standards.
If compliance is not regained, Nasdaq may move to delist the shares, though My Size would have the right to appeal. The company plans to monitor its share price and is considering options such as a potential reverse stock split to restore compliance.
My Size, Inc. reported that its Chief Executive Officer and director, Ronen Luzon, received grants of restricted common stock under the company’s 2017 Equity Incentive Plan on December 15, 2025. He was granted 215,000 restricted shares at a price of $0, bringing his directly held beneficial ownership to 289,335 shares after the transaction. These awards include time-based vesting in three equal annual installments from January 1, 2026 through January 1, 2028, a tranche vesting on December 31, 2025, and performance-based vesting tied to profit and business targets, all subject to continued service.
Luzon also reported indirect ownership through his spouse, Chief Product Officer and Chief Operating Officer Billy Pardo. She received 60,000 restricted shares at a price of $0, increasing the indirectly beneficially owned common stock to 79,750 shares. Her awards follow similar time-based and performance-based vesting schedules under the same plan, conditioned on her continued service to My Size and achievement of specified business and profit targets.
My Size, Inc. reported an insider equity grant to director Oron Branitzky. On December 15, 2025, he received 15,000 shares of common stock as restricted shares under the My Size, Inc. 2017 Equity Incentive Plan at a stated price of $0 per share. Following this award, he beneficially owns 17,500 common shares directly.
The restricted shares are scheduled to vest on December 31, 2025, provided Branitzky continues to serve the company through that date. This filing reflects equity-based compensation rather than an open-market purchase or sale.
My Size, Inc. reported that its Chief Financial Officer received a new equity award. On December 15, 2025, the CFO acquired 30,000 shares of common stock as restricted stock under the company’s 2017 Equity Incentive Plan at a stated price of $0 per share. Following this grant, the officer beneficially owns 32,500 shares directly.
The restricted shares vest in three equal annual installments, with one-third vesting on each of January 1, 2026, January 1, 2027 and January 1, 2028, as long as the officer continues to serve the company through each vesting date.